The San Diego-based biopharmaceutical company, Trius Therapeutics, focuses on discovering, developing, and commercializing antibiotics to treat serious gram-positive bacterial infections, including those caused by drug-resistant strains. Their lead product candidate, TR-701, is an oral and IV oxazolidinone antibiotic with potent activity against these pathogens. With a strong management team experienced in anti-infective drug development, Trius is addressing the urgent need for novel therapeutics to combat the increasing bacterial resistance to existing drugs. Additionally, the company has three other structure-based drug design programs targeting antibacterial agents in their pipeline.